Skip to content

Motor Response to Sildenafil in PD

Motor Response to Acute Challenge to Sildenafil in Parkinsons Disease

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01941732
Enrollment
8
Registered
2013-09-13
Start date
2003-11-30
Completion date
2004-03-31
Last updated
2013-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile Dysfunction, Parkinsons Disease

Brief summary

Sildenafil (Viagra(R))is widely used by men with Parkinsons Disease (PD) and erectile dysfunction. A number of patients have reported that when they take Sildenafil, their need of anti-PD medication is reduced. We hypotheses that sildenafil increases brain blood flow and hence improves the function of specific brain regions, improving motor function. Motor function and cerebral blood flow of 8 patients will be tested before and after Sildenafil intake and before and after anti-PD medication.

Detailed description

Erectile dysfunction can be experienced by up tp 40% of men with Parkinsons Disease (PD). Sildenafil (Viagra(R))is widely used by men with PD and erectile dysfunction. A number of patients have reported that when they take Sildenafil, their need of anti-PD medication is reduced. We hypotheses that sildenafil increases cerebral blood flow in basal ganglia and hence improves the function, improving motor function. Motor function and cerebral blood flow (rCBF) of 8 patients will be tested before and after Sildenafil intake and before and after anti-PD medication. rCBF will be measured by the Xe133 inhalation method and a fast-rotating, brain-dedicated, single photon emission computerized tomograph (SPECT, Tomomatic, 232, Medimatic, Inc., Denmark). Two scans will be perfomed, when patients are i)in normal medicated state and ii) in normal medicated state 1 hour after intake of 100 mg sildenafil. Motor function will be measured i 4 conditions: i)in normal medicated state and ii) in normal medicated state 1 hour after intake of 100 mg sildenafil, iii) after 12 hours of discontiation of anti-PD mediciation and iiii) after 14 hours of discontiation of anti-PD mediciation and 1 hour after intake of 100 mg sildenafil.

Interventions

DRUGSildenafil

Sponsors

Bispebjerg Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Men * Parkinsons disease * Erectile dysfunction * previous tried sildenafil with beneficial effects on motor function

Exclusion criteria

* psychosis * Heart disease

Design outcomes

Primary

MeasureTime frameDescription
Motor function1 hourMotor function assessed by Unified Parkinsons disease Rating Scale, section 3 before and after challenge with Sildenafil and before and after discontinuation of anti-PD medication for 12 hours.

Secondary

MeasureTime frameDescription
Cerebral Blood Flow (rCBF)1 hourchange in rCBF in basal ganglia from before to 1 hour after intake of 100 mg of sildenafil

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026